[SCHEDULE 13G] INTELLIGENT BIO SOLUTIONS INC. Passive Investment Disclosure (>5%)
INTELLIGENT BIO SOLUTIONS INC. ownership disclosure: Armistice Capital, LLC and Steven Boyd report beneficial ownership of 163,571 shares of Common Stock, representing 9.99% of the class.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
INTELLIGENT BIO SOLUTIONS INC. ownership disclosure: Armistice Capital, LLC and Steven Boyd report beneficial ownership of 163,571 shares of Common Stock, representing 9.99% of the class. The filing states Armistice Capital exercises shared voting and dispositive power over these shares under an Investment Management Agreement.
The report is a joint Schedule 13G filing executed by Steven Boyd on 05/15/2026 and identifies Armistice Capital Master Fund Ltd. as the direct holder while the Master Fund disclaims direct beneficial ownership due to the Investment Management Agreement.
Insights
Institutional holder reports a sub-10% passive stake with shared control.
The filing records 163,571 shares or 9.99% beneficial ownership held through Armistice Capital Master Fund Ltd., with voting and dispositive authority exercised by Armistice Capital under an Investment Management Agreement. The Master Fund disclaims direct ownership due to that agreement.
Because the position is reported on a Schedule 13G, the disclosure presents as a passive/beneficial reporting posture; subsequent amendments or a move to Schedule 13D would signal a change in intent.
Shared voting/dispositive power is centralized at the manager level.
The report attributes shared voting and dispositive power of 163,571 shares to Armistice Capital, with Steven Boyd identified as managing member. The filing clarifies the Master Fund is the direct record owner while Armistice Capital manages the holdings.
Future filings may update percent ownership if transactions occur or if the reporting status changes; cash‑flow treatment and transactions are not described in this excerpt.
Key Figures
Key Terms
Schedule 13G regulatory
Investment Management Agreement financial
beneficially owned regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.